Acumen Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary
12/11/2024 15:37
* Acumen Pharmaceuticals Inc ABOS.OQ reported a quarterly
adjusted loss of 50 cents per share for the quarter ended
September 30, lower than the same quarter last year, when the
company reported EPS of -24 cents. The mean expectation of
six analysts for the quarter was for a loss of 36 cents per
share. Wall Street expected results to range from -46 cents
to -25 cents per share.
* Reported revenue was zero; analysts expected zero.
* Acumen Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 50 cents.
* The company reported a quarterly loss of $29.77 million.
* Acumen Pharmaceuticals Inc shares had risen by 29.8% this
quarter and lost 16.1% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 6.7%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is "buy."
Wall Street's median 12-month price target for Acumen
Pharmaceuticals Inc is $11.00
This summary was machine generated from LSEG data November 12 at
03:37 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.36 -0.50 Missed
Jun. 30 2024 -0.28 -0.34 Missed
Mar. 31 2024 -0.26 -0.25 Beat
Dec. 31 2023 -0.26 -0.28 Missed